Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $1.97 up 1.03% from its previous closing price of $1.95. In other words, the price has increased by $1.03 from its previous closing price. On the day, 10.84 million shares were traded. IOVA stock price reached its highest trading level at $2.0 during the session, while it also had its lowest trading level at $1.94.
Ratios:
For a deeper understanding of Iovance Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.27. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 16, 2025, UBS Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 05 ’25 when Kirby Daniel Gordon bought 30,000 shares for $1.84 per share. The transaction valued at 55,200 led to the insider holds 30,000 shares of the business.
Puri Raj K. bought 5,600 shares of IOVA for $9,743 on May 23 ’25. The Chief Regulatory Officer now owns 206,852 shares after completing the transaction at $1.74 per share. On May 14 ’25, another insider, Vogt Frederick G, who serves as the Interim CEO & General Counsel of the company, bought 25,000 shares for $1.69 each. As a result, the insider paid 42,250 and bolstered with 374,646 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 712852160 and an Enterprise Value of 464837184. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.95 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 1.925 whereas that against EBITDA is -1.235.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.87, which has changed by -0.8277972 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is -11.75%, while the 200-Day Moving Average is calculated to be -34.73%.
Shares Statistics:
For the past three months, IOVA has traded an average of 12.37M shares per day and 13432180 over the past ten days. A total of 341.92M shares are outstanding, with a floating share count of 292.67M. Insiders hold about 19.12% of the company’s shares, while institutions hold 53.81% stake in the company. Shares short for IOVA as of 1760486400 were 83612571 with a Short Ratio of 6.76, compared to 1757894400 on 65704715. Therefore, it implies a Short% of Shares Outstanding of 83612571 and a Short% of Float of 25.120002000000003.
Earnings Estimates
At present, 9.0 analysts are actively evaluating the performance of Iovance Biotherapeutics Inc (IOVA) in the stock market.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.12 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$1.0 and -$1.29 for the fiscal current year, implying an average EPS of -$1.13. EPS for the following year is -$0.65, with 9.0 analysts recommending between -$0.42 and -$1.07.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $72.81M this quarter.It ranges from a high estimate of $78.26M to a low estimate of $65.7M. As of . The current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $58.55MFor the next quarter, 11 analysts are estimating revenue of $83.96M. There is a high estimate of $91.6M for the next quarter, whereas the lowest estimate is $75.88M.
A total of 11 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $276.11M, while the lowest revenue estimate was $251M, resulting in an average revenue estimate of $266.68M. In the same quarter a year ago, actual revenue was $164.07MBased on 11 analysts’ estimates, the company’s revenue will be $426.84M in the next fiscal year. The high estimate is $540.4M and the low estimate is $350M.
